Gram-Scale Synthesis of (+)-Discodermolide
J. Am. Chem. Soc., Vol. 122, No. 36, 2000 8655
ing Taxol-resistant lines.8 In this regard, Horwitz et al.9 reported
that 1 was unable to replace Taxol in a newly discovered Taxol-
dependent human lung carcinoma cell line (A549-T12), whereas
the natural products epothilone A and B (3, 4) and eleutherobin
(5) were able to serve as substitutes for Taxol and thus maintain
viability of the cell line.9 Importantly, the Taxol-dependent cell
line proved to be 20-fold more sensitive to 1 in the presence of
low concentrations of Taxol than in its absence.9 The signifi-
cance of these results is 2-fold: (1) (+)-discodermolide may
bind to microtubules at a site distinct from that of Taxol, the
epothilones (3, 4), and eleutherobin (5) and (2) the combination
of (+)-discodermolide and Taxol may constitute a promising
synergistic cancer chemotherapeutic treatment regime. Unfor-
tunately, the current scarcity of natural material (0.002% w/w
from frozen sponge) has precluded further evaluation as an
anticancer agent.
element, while also exploiting the dithiane coupling and σ- and
π-bond construction tactics that had proven so effective in our
syntheses of FK506 and rapamycin.12 Thus, disconnections at
C(8,9), C(14,15), and C(21,22) generated fragments A, B, and
C, each envisioned to arise from a common precursor (CP)
possessing the recurring triad of contiguous stereogenic centers.
Union of A and B via either cuprate chemistry13 or palladium-
catalyzed cross-coupling14 would then lead to an AB fragment
possessing the C(13,14) trisubstituted (Z)-olefin; in turn the ylide
derived from the AB fragment would be coupled via Wittig
olefination with aldehyde C to generate the C(8,9) cis-alkene.
Introduction of the terminal Z-diene would also exploit a Wittig
olefination or like process. Completion of the discodermolide
venture would then only require elaboration of the C(1) lactone
carbonyl, selective incorporation of a carbamate moiety at C(19),
and global deprotection.
The Common Precursor. The critical role of the common
precursor CP demanded development of a route that would be
amenable to large-scale production. To orchestrate the triad of
contiguous stereogenic centers, we selected the Evans syn-aldol
protocol.15 Given that the absolute stereochemistry of (+)-
discodermolide was unknown at the outset (early 1993), we
arbitrarily chose the commercially available (R)-(-) antipode
of methyl 3-hydroxy-2-methylpropionate (6) as starting material.
Ultimately this choice led to the unnatural (-)-antipode of 1.11a
As detailed here, this strategy is equally amenable to the
synthesis of (+)-discodermolide, utilizing the commercially
available (S)-(+) antipode of 6. Although some of the trans-
formations described in this paper were developed during our
initial synthesis of (-)-discodermolide, for clarity of presenta-
tion, all transformations are depicted in the optical series of the
natural product. The absolute stereochemistries with associated
chiropic properties of all intermediates are available in the
Supporting Information.
Not surprisingly the remarkable biological activity and novel
structure, in conjunction with the scarcity of the natural material,
has led to considerable interest in discodermolide as a synthetic
target.10 To date, six total syntheses of discodermolide, including
our first-generation synthesis of the unnatural levorotatory
congener, have been reported.2,11 In this, a full paper, we
describe the evolution of a synthetic strategy which recently
culminated in the preparation of 1 g of the natural congener.11b
Synthetic Plan. Analysis of the discodermolide structure
revealed a repeating triad of contiguous stereocenters (Scheme
1), separated by (Z)-olefinic linkages at C(8,9) and C(13,14).
From the synthetic perspective we sought an efficient, highly
convergent approach taking full advantage of this structural
Scheme 1
Our point of departure for the construction of the common
precursor CP required for natural (+)-discodermolide entailed
protection of hydroxy ester (+)-6 as the p-methoxybenzyl
(PMB) ether (Scheme 2), exploiting the Bundle trichloroimidate
protocol.16 Reduction with LiAlH4 and distillation provided
(11) (a) Smith, A. B., III; Qiu, Y.; Jones, D. R.; Kobayashi, K. J. Am.
Chem. Soc. 1995, 117, 12011. (b) Smith, A. B., III; Kaufman, M. D.;
Beauchamp, T. J.; LaMarche, M. J.; Arimoto, H. Org. Lett. 1999, 1, 1823.
(c) Haried, S. S.; Yang, G.; Strawn, M. A.; Myles, D. C. J. Org. Chem.
1997, 62, 6098.(d) Marshall, J. A.; Lu, Z.-H.; Johns, B. A. J. Org. Chem.
1998, 63, 7885. (e) Paterson, I.; Florence, G. J.; Gerlach, K.; Scott, J. P.
Angew. Chem., Int. Ed. 2000, 39, 2, 377. (f) Halstead, D. P. Ph.D. Thesis,
Harvard University, Cambridge, MA, 1998.
(12) (a) Smith, A. B., III.; Condon, S. M.; McCauley, J. A. Acc. Chem.
Res. 1998, 31, 35. (b) FK506 formal synthesis: Smith, A. B., III; Chen,
K.; Robinson, D. J.; Laakso, L. M.; Hale, K. J. Tetrahedron Lett. 1994, 35,
4271. Also see: Smith, A. B., III; Hale, K. J. Tetrahedron Lett. 1989, 30,
1037. Smith, A. B., III.; Hale, K. J.; Laakso, L. M.; Chen, K.; Rie´ra, A.
Tetrahedron Lett. 1989, 30, 6963. (c) Rapamycin and 27-demethoxyrapa-
mycin total syntheses: Smith, A. B., III; Condon, S. M.; McCauley, J. A.;
Leazer, J. L., Jr.; Leahy, J. W.; Maleczka, R. E., Jr. J. Am. Chem. Soc.
1997, 119, 947. Smith, A. B., III; Condon, S. M.; McCauley, J. A.; Leazer,
J. L., Jr.; Leahy, J. W.; Maleczka, R. E., Jr. J. Am. Chem. Soc. 1997, 119,
962. Smith, A. B., III; Condon, S. M.; McCauley, J. A.; Leazer, J. L., Jr.;
Leahy, J. W.; Maleczka, R. E., Jr. J. Am. Chem. Soc. 1995, 117, 5407.
Also see: Smith, A. B., III; Condon, S. M.; McCauley, J. A.; Leahy, J.
W.; Leazer, J. L., Jr.; Maleczka, R. E., Jr. Tetrahedron Lett. 1994, 35, 4907.
Smith, A. B., III; Maleczka, R. E., Jr.; Leazer, J. L., Jr.; Leahy, J. W.;
McCauley, J. A.; Condon, S. M. Tetrahedron Lett. 1994, 35, 4911.
(13) Lipshutz, B. H.; Sengupta, S. In Organic Reactions; Paquette, L.
A., Ed.; John Wiley: New York, 1992; Vol. 41, Chapter 2.
(8) Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R.
E.; Day, B. W.; Hamel, E. Mol. Pharm. 1997, 52, 613.
(9) Martello, L. A.; McDiad, H. M.; Regl, D. L.; Yang, C. H.; Meng,
D.; Pettus, T. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith,
A. B., III; Horwitz, S. B. Clin. Cancer Res. 2000, 6, 1978.
(10) For synthetic approaches to discodermolide, see: (a) Paterson, I.;
Wren, S. P. J. Chem. Soc., Chem. Commun. 1993, 1790. (b) Clark, D. L.;
Heathcock, C. H. J. Org. Chem. 1993, 58, 5878. (c) Golec, J. M. C.; Jones,
S. D. Tetrahedron Lett. 1993, 34, 8159. (d) Evans, P. L.; Golec, J. M. C.;
Gillespie, R. J. Ibid. 1993, 34, 8163. (e) Golec, J. M. C.; Gillespie, R. J.
Ibid. 1993, 34, 8167. (f) Yang, G.; Myles, D. C. Ibid. 1994, 35, 1313. (g)
Yang, G.; Myles, D. C. Ibid. 1994, 35, 2503. (h) Paterson, I.; Schlapbach,
A. Synlett 1995, 498. (j) Miyazawa, M.; Oonuma, S.; Maruyama, K.;
Miyashita, M. Chem. Lett. 1997, 1191. (j) Miyazawa, M.; Oonuma, S.;
Maruyama, K.; Miyashita, M. Chem. Lett. 1997, 1193. (k) Evans, D. A.;
Allison, B. D.; Yang, M. G. Tetrahedron Lett. 1999, 40, 4457-4460. (l)
Evans, D. A.; Halstead, D. P.; Allison, B. D. Tetrahedron Lett. 1999, 40,
4461-4462. (m) Hoffman, H. M. R.; Misske, A. M.; Tetrehedron 1999,
55, 4315. (n) Filla, S. A.; Song, J. J.; Chem, L.; Masamune, S.; Tetrahedron
Lett. 1999, 5449.
(14) (a) Hayashi, T.; Konishi, M.; Kobori, Y.; Kumada, M.; Higuchi,
T.; Hirotsu, K. J. Am. Chem. Soc. 1984, 106, 158. (b) Negishi, E.; Valente,
L. F.; Kobayashi, M. Ibid. 1980, 102, 3298. (c) Miyaura, N.; Ishiyama, T.;
Sasaki, H.; Ishikawa, M.; Satoh, M.; Suzuki, A. Ibid. 1989, 111, 314.
(15) Evans, D. A.; Bartroli, J.; Shih, T. L. J. Am. Chem. Soc. 1981, 103,
2127.